Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 General data of the study population

From: T2 mapping of molecular subtypes of WHO grade II/III gliomas

 IDH-mut (n = 18)IDH-wt (n = 12)p-value*
age, yr. (mean, range)41,32 ± 12,3 [28–74]55,69 ± 16,39 [34–81]0,0105
A238,13 ± 11,53 [28–57]64,22 ± 18,25 [41–81]
AA342,55 ± 12,81 [29–74]51,42 ± 14,73 [34–74]
sex (no.)n = 18n = 12< 0,0001
female9 (50%)1 (8,33%)
male9 (50%)11 (91,67%)
tumor graden = 18n = 12
A25 (27,78%)4 (33,33%)
AA313 (72,22%)8 (66,67%)
tumor localizationn = 18n = 12< 0,0001**
fronto-parietalfrontal (38,89%)
parietal (16,67%)
frontoparietal (11,1%)
frontal (16,67%)
parietal (16,67%)
otherfronto-parieto-temporal (16,67%)
temporal (11,1%)
parieto-temporal (5,56%)
thalamic (25%)
temporal (16,67%)
frontotemporal (8,33%)
corpus callosum (8,33%)
5 single lesions (8,33%)
 
  1. *All p-values relate to the difference between IDH-mut and IDH-wt independently of the tumor grade. **This p-value concerns to fronto-parietal or not fronto-parietal localization in IDH-mut and IDH-wt tumors